ID   AMPD2_HUMAN             Reviewed;         879 AA.
AC   Q01433; B4DK50; B4DZI5; E9PNG0; Q14856; Q14857; Q16686; Q16687;
AC   Q16688; Q16729; Q5T693; Q5T695; Q96IA1; Q9UDX8; Q9UDX9; Q9UMU4;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=AMP deaminase 2;
DE            EC=3.5.4.6;
DE   AltName: Full=AMP deaminase isoform L;
GN   Name=AMPD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=1429593;
RA   Bausch-Jurken M.T., Mahnke-Zizelman D.K., Morisaki T., Sabina R.L.;
RT   "Molecular cloning of AMP deaminase isoform L. Sequence and bacterial
RT   expression of human AMPD2 cDNA.";
RL   J. Biol. Chem. 267:22407-22413(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=8526848;
RA   Van den Bergh F., Sabina R.L.;
RT   "Characterization of human AMP deaminase 2 (AMPD2) gene expression
RT   reveals alternative transcripts encoding variable N-terminal
RT   extensions of isoform L.";
RL   Biochem. J. 312:401-410(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=8764830; DOI=10.1016/0167-4781(96)00089-9;
RA   Mahnke-Zizelman D.K., van den Bergh F., Bausch-Jurken M.T., Eddy R.,
RA   Sait S., Shows T.B., Sabina R.L.;
RT   "Cloning, sequence and characterization of the human AMPD2 gene:
RT   evidence for transcriptional regulation by two closely spaced
RT   promoters.";
RL   Biochim. Biophys. Acta 1308:122-132(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS EX1B-3 AND 5), AND
RP   VARIANT VAL-522.
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM EX1A-2-3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-118; SER-151; THR-188
RP   AND SER-190, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76 AND SER-190, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168 AND SER-190, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-190, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   FUNCTION, TISSUE SPECIFICITY, AND VARIANTS PCH9 HIS-674; ASP-778 AND
RP   TYR-793.
RX   PubMed=23911318; DOI=10.1016/j.cell.2013.07.005;
RA   Akizu N., Cantagrel V., Schroth J., Cai N., Vaux K., McCloskey D.,
RA   Naviaux R.K., Van Vleet J., Fenstermaker A.G., Silhavy J.L.,
RA   Scheliga J.S., Toyama K., Morisaki H., Sonmez F.M., Celep F.,
RA   Oraby A., Zaki M.S., Al-Baradie R., Faqeih E.A., Saleh M.A.,
RA   Spencer E., Rosti R.O., Scott E., Nickerson E., Gabriel S.,
RA   Morisaki T., Holmes E.W., Gleeson J.G.;
RT   "AMPD2 regulates GTP synthesis and is mutated in a potentially
RT   treatable neurodegenerative brainstem disorder.";
RL   Cell 154:505-517(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100; SER-118; SER-134;
RP   SER-168; SER-190 AND SER-192, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100; SER-168 AND
RP   SER-190, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   INVOLVEMENT IN SPG63.
RX   PubMed=24482476; DOI=10.1126/science.1247363;
RA   Novarino G., Fenstermaker A.G., Zaki M.S., Hofree M., Silhavy J.L.,
RA   Heiberg A.D., Abdellateef M., Rosti B., Scott E., Mansour L.,
RA   Masri A., Kayserili H., Al-Aama J.Y., Abdel-Salam G.M., Karminejad A.,
RA   Kara M., Kara B., Bozorgmehri B., Ben-Omran T., Mojahedi F.,
RA   Mahmoud I.G., Bouslam N., Bouhouche A., Benomar A., Hanein S.,
RA   Raymond L., Forlani S., Mascaro M., Selim L., Shehata N.,
RA   Al-Allawi N., Bindu P.S., Azam M., Gunel M., Caglayan A., Bilguvar K.,
RA   Tolun A., Issa M.Y., Schroth J., Spencer E.G., Rosti R.O., Akizu N.,
RA   Vaux K.K., Johansen A., Koh A.A., Megahed H., Durr A., Brice A.,
RA   Stevanin G., Gabriel S.B., Ideker T., Gleeson J.G.;
RT   "Exome sequencing links corticospinal motor neuron disease to common
RT   neurodegenerative disorders.";
RL   Science 343:506-511(2014).
CC   -!- FUNCTION: AMP deaminase plays a critical role in energy
CC       metabolism. Catalyzes the deamination of AMP to IMP and plays an
CC       important role in the purine nucleotide cycle.
CC       {ECO:0000269|PubMed:23911318}.
CC   -!- CATALYTIC ACTIVITY: AMP + H(2)O = IMP + NH(3).
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via salvage pathway;
CC       IMP from AMP: step 1/1.
CC   -!- SUBUNIT: Homotetramer.
CC   -!- INTERACTION:
CC       P23109:AMPD1; NbExp=4; IntAct=EBI-11957578, EBI-2959675;
CC       O95273:CCNDBP1; NbExp=3; IntAct=EBI-8796759, EBI-748961;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-8796759, EBI-710997;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=Ex1B-2-3;
CC         IsoId=Q01433-1; Sequence=Displayed;
CC       Name=Ex1A-2-3;
CC         IsoId=Q01433-2; Sequence=VSP_001271, VSP_001272;
CC       Name=Ex1A-3;
CC         IsoId=Q01433-3; Sequence=VSP_001274;
CC       Name=Ex1B-3;
CC         IsoId=Q01433-4; Sequence=VSP_001273;
CC       Name=5;
CC         IsoId=Q01433-5; Sequence=VSP_045975;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in cerebellum.
CC       {ECO:0000269|PubMed:23911318}.
CC   -!- DISEASE: Pontocerebellar hypoplasia 9 (PCH9) [MIM:615809]: A form
CC       of pontocerebellar hypoplasia, a disorder characterized by
CC       structural defects of the pons and cerebellum, evident upon brain
CC       imaging. PCH9 features include severely delayed psychomotor
CC       development, progressive microcephaly, spasticity, seizures, and
CC       brain abnormalities, including brain atrophy, thin corpus
CC       callosum, and delayed myelination. {ECO:0000269|PubMed:23911318}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Spastic paraplegia 63, autosomal recessive (SPG63)
CC       [MIM:615686]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. {ECO:0000269|PubMed:24482476}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the adenosine and AMP deaminases family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91029; AAA62127.1; -; mRNA.
DR   EMBL; M91029; AAA62126.1; -; mRNA.
DR   EMBL; S47833; AAA11725.1; -; mRNA.
DR   EMBL; U16267; AAC50306.1; -; mRNA.
DR   EMBL; U16268; AAC50307.1; -; mRNA.
DR   EMBL; U16269; AAB06511.1; -; Genomic_RNA.
DR   EMBL; U16270; AAC50308.1; -; mRNA.
DR   EMBL; U16272; AAD56302.1; -; Genomic_DNA.
DR   EMBL; U16271; AAD56302.1; JOINED; Genomic_DNA.
DR   EMBL; U16272; AAC50309.2; -; Genomic_DNA.
DR   EMBL; U16271; AAC50309.2; JOINED; Genomic_DNA.
DR   EMBL; U16272; AAD56303.1; -; Genomic_DNA.
DR   EMBL; U16271; AAD56303.1; JOINED; Genomic_DNA.
DR   EMBL; AK296394; BAG59062.1; -; mRNA.
DR   EMBL; AK302939; BAG64097.1; -; mRNA.
DR   EMBL; AL355310; CAI19305.1; -; Genomic_DNA.
DR   EMBL; AL355310; CAI19307.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56396.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56399.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56401.1; -; Genomic_DNA.
DR   EMBL; BC007711; AAH07711.1; -; mRNA.
DR   EMBL; BC075844; AAH75844.1; -; mRNA.
DR   CCDS; CCDS30796.1; -. [Q01433-3]
DR   CCDS; CCDS58016.1; -. [Q01433-5]
DR   CCDS; CCDS76186.1; -. [Q01433-4]
DR   CCDS; CCDS804.1; -. [Q01433-2]
DR   CCDS; CCDS805.1; -. [Q01433-1]
DR   PIR; A44313; A44313.
DR   PIR; S59994; S59994.
DR   PIR; S59995; S59995.
DR   PIR; S59998; S59998.
DR   PIR; S59999; S59999.
DR   PIR; S60000; S60000.
DR   RefSeq; NP_001244289.1; NM_001257360.1. [Q01433-1]
DR   RefSeq; NP_001244290.1; NM_001257361.1. [Q01433-5]
DR   RefSeq; NP_001295099.1; NM_001308170.1. [Q01433-4]
DR   RefSeq; NP_004028.3; NM_004037.7. [Q01433-1]
DR   RefSeq; NP_631895.1; NM_139156.3. [Q01433-2]
DR   RefSeq; NP_981949.1; NM_203404.1. [Q01433-3]
DR   UniGene; Hs.82927; -.
DR   PDB; 4NO3; X-ray; 1.70 A; C=165-173.
DR   PDB; 4NO5; X-ray; 2.10 A; C=165-173.
DR   PDBsum; 4NO3; -.
DR   PDBsum; 4NO5; -.
DR   ProteinModelPortal; Q01433; -.
DR   SMR; Q01433; -.
DR   BioGrid; 106768; 24.
DR   IntAct; Q01433; 7.
DR   STRING; 9606.ENSP00000256578; -.
DR   BindingDB; Q01433; -.
DR   ChEMBL; CHEMBL2997; -.
DR   iPTMnet; Q01433; -.
DR   PhosphoSitePlus; Q01433; -.
DR   BioMuta; AMPD2; -.
DR   DMDM; 12644375; -.
DR   EPD; Q01433; -.
DR   MaxQB; Q01433; -.
DR   PaxDb; Q01433; -.
DR   PeptideAtlas; Q01433; -.
DR   PRIDE; Q01433; -.
DR   Ensembl; ENST00000256578; ENSP00000256578; ENSG00000116337. [Q01433-1]
DR   Ensembl; ENST00000342115; ENSP00000345498; ENSG00000116337. [Q01433-2]
DR   Ensembl; ENST00000358729; ENSP00000351573; ENSG00000116337. [Q01433-4]
DR   Ensembl; ENST00000393688; ENSP00000377292; ENSG00000116337. [Q01433-3]
DR   Ensembl; ENST00000528454; ENSP00000437164; ENSG00000116337. [Q01433-5]
DR   Ensembl; ENST00000528667; ENSP00000436541; ENSG00000116337. [Q01433-1]
DR   GeneID; 271; -.
DR   KEGG; hsa:271; -.
DR   UCSC; uc001dyb.3; human. [Q01433-1]
DR   CTD; 271; -.
DR   DisGeNET; 271; -.
DR   GeneCards; AMPD2; -.
DR   HGNC; HGNC:469; AMPD2.
DR   HPA; HPA027137; -.
DR   HPA; HPA045760; -.
DR   HPA; HPA050590; -.
DR   MalaCards; AMPD2; -.
DR   MIM; 102771; gene.
DR   MIM; 615686; phenotype.
DR   MIM; 615809; phenotype.
DR   neXtProt; NX_Q01433; -.
DR   OpenTargets; ENSG00000116337; -.
DR   Orphanet; 401805; Autosomal recessive spastic paraplegia type 63.
DR   Orphanet; 369920; Pontocerebellar hypoplasia type 9.
DR   PharmGKB; PA24777; -.
DR   eggNOG; KOG1096; Eukaryota.
DR   eggNOG; COG1816; LUCA.
DR   GeneTree; ENSGT00390000008190; -.
DR   HOGENOM; HOG000092200; -.
DR   HOVERGEN; HBG050494; -.
DR   InParanoid; Q01433; -.
DR   KO; K01490; -.
DR   OMA; RCFLHQS; -.
DR   OrthoDB; EOG091G01OU; -.
DR   PhylomeDB; Q01433; -.
DR   TreeFam; TF300439; -.
DR   BioCyc; MetaCyc:HS04008-MONOMER; -.
DR   Reactome; R-HSA-74217; Purine salvage.
DR   SABIO-RK; Q01433; -.
DR   UniPathway; UPA00591; UER00663.
DR   ChiTaRS; AMPD2; human.
DR   GeneWiki; AMPD2; -.
DR   GenomeRNAi; 271; -.
DR   PRO; PR:Q01433; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000116337; -.
DR   ExpressionAtlas; Q01433; baseline and differential.
DR   Genevisible; Q01433; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0003876; F:AMP deaminase activity; IGI:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046033; P:AMP metabolic process; IEA:Ensembl.
DR   GO; GO:0046034; P:ATP metabolic process; IEA:Ensembl.
DR   GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl.
DR   GO; GO:0052652; P:cyclic purine nucleotide metabolic process; IMP:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; IGI:MGI.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; IEA:Ensembl.
DR   GO; GO:0046039; P:GTP metabolic process; IEA:Ensembl.
DR   GO; GO:0006188; P:IMP biosynthetic process; IGI:MGI.
DR   GO; GO:0032264; P:IMP salvage; IEA:UniProtKB-UniPathway.
DR   GO; GO:0043101; P:purine-containing compound salvage; TAS:Reactome.
DR   CDD; cd01319; AMPD; 1.
DR   InterPro; IPR006650; A/AMP_deam_AS.
DR   InterPro; IPR001365; A/AMP_deaminase_dom.
DR   InterPro; IPR006329; AMPD.
DR   InterPro; IPR029749; AMPD2.
DR   InterPro; IPR032466; Metal_Hydrolase.
DR   PANTHER; PTHR11359; PTHR11359; 1.
DR   PANTHER; PTHR11359:SF16; PTHR11359:SF16; 1.
DR   Pfam; PF00962; A_deaminase; 1.
DR   PIRSF; PIRSF001251; AMP_deaminase_met; 1.
DR   SFLD; SFLDF00063; AMP_deaminase; 1.
DR   SUPFAM; SSF51556; SSF51556; 2.
DR   TIGRFAMs; TIGR01429; AMP_deaminase; 1.
DR   PROSITE; PS00485; A_DEAMINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Hereditary spastic paraplegia; Hydrolase;
KW   Metal-binding; Methylation; Neurodegeneration; Nucleotide metabolism;
KW   Phosphoprotein; Polymorphism; Reference proteome; Zinc.
FT   CHAIN         1    879       AMP deaminase 2.
FT                                /FTId=PRO_0000194407.
FT   REGION      489    494       Substrate binding. {ECO:0000250}.
FT   REGION      765    768       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    709    709       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10104}.
FT   METAL       418    418       Zinc; catalytic. {ECO:0000250}.
FT   METAL       420    420       Zinc; catalytic. {ECO:0000250}.
FT   METAL       687    687       Zinc; catalytic. {ECO:0000250}.
FT   METAL       764    764       Zinc; catalytic. {ECO:0000250}.
FT   BINDING     420    420       Substrate. {ECO:0000250}.
FT   BINDING     690    690       Substrate. {ECO:0000250}.
FT   MOD_RES      76     76       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES      99     99       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q9DBT5}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     118    118       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     134    134       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     145    145       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9DBT5}.
FT   MOD_RES     151    151       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     168    168       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     188    188       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     190    190       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     192    192       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    128       MRNRGQGLFRLRSRCFLHQSLPLGAGRRKGLDVAEPGPSRC
FT                                RSDSPAVAAVVPAMASYPSGSGKPKAKYPFKKRASLQASTA
FT                                APEARGGLGAPPLQSARSLPGPAPCLKHFPLDLRTSMDGKC
FT                                KEIAE -> MLTFLPSPQ (in isoform Ex1A-3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001274.
FT   VAR_SEQ       1    128       MRNRGQGLFRLRSRCFLHQSLPLGAGRRKGLDVAEPGPSRC
FT                                RSDSPAVAAVVPAMASYPSGSGKPKAKYPFKKRASLQASTA
FT                                APEARGGLGAPPLQSARSLPGPAPCLKHFPLDLRTSMDGKC
FT                                KEIAE -> MWQSQAPAGAAQTPPLSPPWSQPWHPIHLALA
FT                                SPRPNIPLRSGPACRPPLQLQ (in isoform Ex1B-
FT                                3). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_001273.
FT   VAR_SEQ       1    118       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045975.
FT   VAR_SEQ       1     81       Missing (in isoform Ex1A-2-3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_001271.
FT   VAR_SEQ      82     84       AAP -> MAS (in isoform Ex1A-2-3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_001272.
FT   VARIANT     522    522       I -> V (in dbSNP:rs201254826).
FT                                {ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_069105.
FT   VARIANT     674    674       R -> H (in PCH9; dbSNP:rs587777395).
FT                                {ECO:0000269|PubMed:23911318}.
FT                                /FTId=VAR_071158.
FT   VARIANT     778    778       E -> D (in PCH9; dbSNP:rs587777392).
FT                                {ECO:0000269|PubMed:23911318}.
FT                                /FTId=VAR_071193.
FT   VARIANT     793    793       D -> Y (in PCH9; dbSNP:rs587777394).
FT                                {ECO:0000269|PubMed:23911318}.
FT                                /FTId=VAR_071159.
FT   CONFLICT    207    207       R -> G (in Ref. 1; AAA11725).
FT                                {ECO:0000305}.
FT   CONFLICT    811    811       V -> I (in Ref. 4; BAG59062).
FT                                {ECO:0000305}.
SQ   SEQUENCE   879 AA;  100688 MW;  5BD9BBF5AA41BE8F CRC64;
     MRNRGQGLFR LRSRCFLHQS LPLGAGRRKG LDVAEPGPSR CRSDSPAVAA VVPAMASYPS
     GSGKPKAKYP FKKRASLQAS TAAPEARGGL GAPPLQSARS LPGPAPCLKH FPLDLRTSMD
     GKCKEIAEEL FTRSLAESEL RSAPYEFPEE SPIEQLEERR QRLERQISQD VKLEPDILLR
     AKQDFLKTDS DSDLQLYKEQ GEGQGDRSLR ERDVLEREFQ RVTISGEEKC GVPFTDLLDA
     AKSVVRALFI REKYMALSLQ SFCPTTRRYL QQLAEKPLET RTYEQGPDTP VSADAPVHPP
     ALEQHPYEHC EPSTMPGDLG LGLRMVRGVV HVYTRREPDE HCSEVELPYP DLQEFVADVN
     VLMALIINGP IKSFCYRRLQ YLSSKFQMHV LLNEMKELAA QKKVPHRDFY NIRKVDTHIH
     ASSCMNQKHL LRFIKRAMKR HLEEIVHVEQ GREQTLREVF ESMNLTAYDL SVDTLDVHAD
     RNTFHRFDKF NAKYNPIGES VLREIFIKTD NRVSGKYFAH IIKEVMSDLE ESKYQNAELR
     LSIYGRSRDE WDKLARWAVM HRVHSPNVRW LVQVPRLFDV YRTKGQLANF QEMLENIFLP
     LFEATVHPAS HPELHLFLEH VDGFDSVDDE SKPENHVFNL ESPLPEAWVE EDNPPYAYYL
     YYTFANMAML NHLRRQRGFH TFVLRPHCGE AGPIHHLVSA FMLAENISHG LLLRKAPVLQ
     YLYYLAQIGI AMSPLSNNSL FLSYHRNPLP EYLSRGLMVS LSTDDPLQFH FTKEPLMEEY
     SIATQVWKLS SCDMCELARN SVLMSGFSHK VKSHWLGPNY TKEGPEGNDI RRTNVPDIRV
     GYRYETLCQE LALITQAVQS EMLETIPEEA GITMSPGPQ
//
